Alzheimer's Disease Pipeline Insight 2025: Emerging Therapies and Key Companies

Strategic Insights -

DelveInsight's analysis highlights that the Alzheimer's Disease pipeline comprises over 110 key companies actively engaged in developing more than 120 treatment therapies. The report provides comprehensive insights into the clinical development activities of the Alzheimer's Disease therapeutics market, including the therapeutic assessment by product type, stage, route of administration, and molecule type. Notable pipeline candidates in various stages of development include AR1001, NE3107, LY3372689, CT1812, ABBV-916, ALX-001, and more.

Key Takeaways:

  • DelveInsight's Alzheimer's Disease pipeline report highlights a dynamic landscape, featuring over 110 active companies developing more than 120 therapeutic candidates for Alzheimer's treatment. Leading industry players, including AriBio, Eli Lilly, Cognition Therapeutics, AbbVie, Allyx Therapeutics, Cassava Sciences, BioVie, Novo Nordisk, Alector, Longeveron, TrueBinding, VT BIO, Luye Pharma, Lexeo Therapeutics, Merck, Regeneration Biomedical, Alnylam, Sinotau Pharmaceutical, Eisai, Shanghai Hengrui, and others, are advancing novel therapies to enhance the treatment paradigm.
  • Notable pipeline candidates in various stages of development include AR1001, NE3107, LY3372689, CT1812, ABBV-916, ALX-001, and more.
  • In July 2024, the U.S. FDA approved Kisunla(TM) (donanemab-azbt) for adults with early symptomatic Alzheimer's disease. Clinical studies demonstrated a 35% reduction in cognitive and functional decline over 18 months compared to placebo and a 39% lower risk of progression to the next disease stage.
  • Kisunla is notable for its limited-duration treatment regimen, with nearly half of the study participants completing the course within 12 months.
  • The report provides detailed insights into the key companies that are developing therapies in the Alzheimer's Disease Market.
  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer's Disease treatment.

Statistics:

  • Over 110 companies are currently working on developing therapies for Alzheimer's disease.
  • More than 120 therapeutic candidates are in development for Alzheimer's Disease treatment.
  • The therapeutic pipeline includes 35% reduction in cognitive and functional decline over 18 months.
  • The pipeline includes 39% lower risk of progression to the next disease stage.

Sources:

  • DelveInsight's Alzheimer's disease Pipeline Insight, 2025 report
  • www.delveinsight.com
  • www.abnewswire.com
  • M2 PressWIRE